Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial

Rodriguez-Moreno, J. F.de Velasco, G.Alvarez-Fernandez, C.Collado, R.Fernandez-Rodriguez, R.Vazquez Estevez, S.Virizuela Echaburu, J. A.Gajate Borau, P.Font, A.Lainez, N.Sevillano Fernandez, E.Ruiz, S.Beltran, L.Rodriguez-Antona, C.Berraondo, P.Garcia-Donas, J.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27617enImpact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trialconference outputopen access10.1016/j.annonc.2020.08.8331569-8041http://www.annalsofoncology.org/article/S0923753420408294/pdf573469101049